Are Conazit 200 mg and Itrovance 200 mg (itraconazole 200 mg) therapeutically equivalent and interchangeable for treating fungal infections?

Conazit 200 vs Itrovance 200: Therapeutic Equivalence

Conazit 200 mg and Itrovance 200 mg are NOT therapeutically equivalent or interchangeable based on available FDA labeling information, which indicates Conazit is contraindicated for use on wounds or damaged skin and in children under 12 years, suggesting it may be a topical formulation rather than a systemic itraconazole product. 1

Critical Distinction in Product Formulations

The FDA labeling reveals fundamental differences between these products:

• Conazit 200: The label explicitly states "DO NOT USE: ON WOUNDS OR DAMAGED SKIN. CHILDREN UNDER 12 YEARS OLD, CONSULT A DOCTOR" 1, which is characteristic of topical antifungal preparations, not systemic itraconazole capsules used for invasive fungal infections.

• Itrovance 200: The labeling warns "IF CONDITION WORSENS, OR IF SYMPTOMS PERSIST FOR MORE THAN 7 DAYS OR CLEAR UP AND OCCUR AGAIN WITHIN A FEW DAYS, DISCONTINUE USE" 1, which also suggests a topical or superficial infection treatment rather than systemic therapy.

Systemic Itraconazole 200 mg Dosing Standards

When prescribing systemic itraconazole 200 mg for fungal infections, established guidelines specify:

• Endemic mycoses: Itraconazole 200 mg orally twice daily for at least 12 months following initial amphotericin B therapy 2
• Esophageal candidiasis (fluconazole-refractory): Itraconazole solution 200 mg daily for 14-21 days 2
• Prophylaxis in HIV: Itraconazole 200 mg orally daily reduces invasive fungal infections in patients with CD4 counts <200 cells/μL 2

Bioavailability and Formulation Considerations

Different itraconazole formulations are NOT interchangeable due to significant pharmacokinetic variations:

• Conventional itraconazole capsules have variable absorption that is pH-dependent 3
• Itraconazole oral solution has improved bioavailability compared to capsules 4
• Super-bioavailable itraconazole (SUBA-ITZ) formulations allow lower dosing while achieving similar serum concentrations, and the FDA explicitly states these formulations are not interchangeable with conventional itraconazole 3
• Drug errors commonly occur when transitioning between formulations 3

Clinical Recommendation

Do not substitute Conazit 200 for Itrovance 200 (or vice versa) without verifying:

1. The actual active pharmaceutical ingredient and formulation type (topical vs. systemic)
2. Whether the product is FDA-approved systemic itraconazole for the intended indication
3. The specific bioavailability characteristics of each formulation
4. Appropriate dosing for the target fungal infection

For systemic fungal infections requiring itraconazole 200 mg, prescribe only FDA-approved systemic itraconazole formulations (capsules, oral solution, or SUBA-itraconazole) with established pharmacokinetics and clinical efficacy data 5, 4. The labeling warnings for both Conazit and Itrovance suggest these may not be appropriate for systemic fungal infections requiring standard itraconazole therapy 1.